Stephen D. Simpson

Despite a lower cost base and low apparent multiples, Alpha Natural Resources has a long way to go.

Santarus is a high-quality addition to what was already a good business in Salix.

Boston Scientific has made major strides in cleaning up its act, and the Street has certainly noticed.

Another disappointing quarter for system placements will weigh on the shares of Intuitive Surgical, a former high-flying stock.

A rebound in recon and ongoing growth in neuro have pushed Stryker's shares back to a 52-week high.

Abbott Laboratories still has work to do, but the progress on margins and strength in diagnostics are encouraging.

Better-than-expected CRM performance and a suite of new products have the Street feeling bullish about St. Jude once again.

JNJ shares continue to outpace most of its rivals in pharmaceuticals and medical devices, largely on the strength of the company's drug business.

While Varian's competitors are improving and reimbursement is unpredictable, Varian remains a tremendously well-run company in a mission-critical hospital equipment market.

Once a growth darling, Edwards Lifesciences has struggled to live up to elevated expectations.

Will Pfizer's potential split unlock hidden value or growth potential?

Johnson & Johnson looks likely to get good value from its weak Ortho Clinical Diagnostics unit.

Deals helped J&J fix its drug business -- could the same be true in devices?

Though not cheap, Cooper could be positioning for some significant revenue, margin, and cash flow improvements.

One of the best ways to avoid resenting saving for retirement is to better understand its source.

Learn the secrets of investing in this often-intimidating sector.

Recent guidance may be aimed at resetting future expectations.

It's a boring company, yes, but sometimes boring is where you want to be.

The pork producer looks like it's doing a little better in this protein glut.

Can Borders make it to the other side without a superstar bestseller?